Vertex Pharmaceuticals, Inc. (VRTX)
515.19
-5.47
(-1.05%)
USD |
NASDAQ |
Nov 20, 16:00
516.99
+1.80
(+0.35%)
After-Hours: 19:22
Vertex Pharmaceuticals Gross Profit (TTM) : 11.15B for Sept. 30, 2026
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 11.15B |
| June 30, 2026 | 10.94B |
| March 31, 2026 | 10.66B |
| December 31, 2025 | 10.42B |
| September 30, 2025 | 10.13B |
| June 30, 2025 | 9.808B |
| March 31, 2025 | 9.492B |
| December 31, 2024 | 9.454B |
| September 30, 2024 | 9.142B |
| June 30, 2024 | 8.922B |
| March 31, 2024 | 8.836B |
| December 31, 2023 | 8.577B |
| September 30, 2023 | 8.392B |
| June 30, 2023 | 8.209B |
| March 31, 2023 | 7.922B |
| December 31, 2022 | 7.668B |
| September 30, 2022 | 7.517B |
| June 30, 2022 | 7.290B |
| March 31, 2022 | 6.983B |
| December 31, 2021 | 6.700B |
| September 30, 2021 | 6.321B |
| June 30, 2021 | 5.927B |
| March 31, 2021 | 5.678B |
| December 31, 2020 | 5.473B |
| September 30, 2020 | 5.258B |
| Date | Value |
|---|---|
| June 30, 2020 | 4.706B |
| March 31, 2020 | 4.170B |
| December 31, 2019 | 3.583B |
| September 30, 2019 | 3.103B |
| June 30, 2019 | 2.967B |
| March 31, 2019 | 2.820B |
| December 31, 2018 | 2.633B |
| September 30, 2018 | 2.459B |
| June 30, 2018 | 2.293B |
| March 31, 2018 | 2.113B |
| December 31, 2017 | 2.212B |
| September 30, 2017 | 2.042B |
| June 30, 2017 | 1.897B |
| March 31, 2017 | 1.812B |
| December 31, 2016 | 1.492B |
| September 30, 2016 | 1.447B |
| June 30, 2016 | 1.365B |
| March 31, 2016 | 1.128B |
| December 31, 2015 | 898.61M |
| September 30, 2015 | 667.45M |
| June 30, 2015 | 545.92M |
| March 31, 2015 | 517.82M |
| December 31, 2014 | 494.89M |
| September 30, 2014 | 701.42M |
| June 30, 2014 | 739.46M |
Gross Profit Definition
Annual, Interim and Preliminary Items - Commercial, Other Financial Companies
Gross Profit (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 3.874B |
| Gilead Sciences, Inc. | 24.85B |
| Regeneron Pharmaceuticals, Inc. | 13.98B |
| Amgen, Inc. | 28.84B |
| TG Therapeutics, Inc. | 742.84M |